Role of acetazolamide and hydrochlorothiazide followed by furosemide in treating edema

Comparing the effect of using furosemide following acetazolamide and hydrochlorothiazide with furosemide and hydrochlorothiazide in treating refractory edema

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT2014081518798N1

Enrollment

Registered

2014-09-08

Start date

2014-08-16

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Refractory edema in nephrotic syndrome. Incl.: congenital nephrotic syndrome, lipoid nephrosis

Interventions

Intervention 1: Intervention Arm: Using 250 mg,1 tablet, acetazolamide and 50 mg,1 tablet, hydrocholorothiazide daily for one week followed by 2 weeks use of 40mg ,1 tablet, furosemide daily. Interven

Treatment - Drugs

Intervention Arm: Using 250 mg,1 tablet, acetazolamide and 50 mg,1 tablet, hydrocholorothiazide daily for one week followed by 2 weeks use of 40mg ,1 tablet, furosemide daily.

Control Arm: Using 40 mg, 1 tablet, furosemide and 50 mg, 1 tablet, hydrocholorothiazide daily for one week followed by 2 weeks use of 40 mg,1 tablet, furosemide daily.

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion Criteria: 1. Having refractory edema due to nephrotic syndrome 2. Normal BUN and creatinine 3. Being able to come for weekly visit 4. More than 18 years of age 5. Signing the informed consent form Exclusion Criteria: 1. Hypokalemia 2. Pregnancy 3. Renal transplant 4. Present malignancy 5. Severe acidosis 6. Using NSAIDs 7. Having another causes of edema including liver cirrhosis, heart failure

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Weight. Timepoint: 3 weeks after the starting the drugs. Method of measurement: Using a scale.	—

Secondary

Measure	Time frame
Blood Urea Nitrogen. Timepoint: 3 weeks after starting the drugs. Method of measurement: By labratory.;Serum Creatinine. Timepoint: 3 weeks after starting the drugs. Method of measurement: By labratory.;Serum Sodium. Timepoint: 3 weeks after starting the drugs. Method of measurement: By labratory.;Serum Potassium. Timepoint: 3 weeks after starting the drugs. Method of measurement: By labratory.;Serum Triglycerides. Timepoint: 3 weeks after starting the drugs. Method of measurement: By labratory.;Serum Cholesterol. Timepoint: 3 weeks after starting the drugs. Method of measurement: By labratory.	—

Measure

Time frame

Blood Urea Nitrogen. Timepoint: 3 weeks after starting the drugs. Method of measurement: By labratory.;Serum Creatinine. Timepoint: 3 weeks after starting the drugs. Method of measurement: By labratory.;Serum Sodium. Timepoint: 3 weeks after starting the drugs. Method of measurement: By labratory.;Serum Potassium. Timepoint: 3 weeks after starting the drugs. Method of measurement: By labratory.;Serum Triglycerides. Timepoint: 3 weeks after starting the drugs. Method of measurement: By labratory.;Serum Cholesterol. Timepoint: 3 weeks after starting the drugs. Method of measurement: By labratory.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMohammad Amin Fallahzadeh

Shiraz Medical School

fallahzadm@sums.ac.ir, aminfa91@gmail.com+98 71 1646 6976

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026